ABBV Stock Recent News

AbbVie (ABBV -0.36%) is a drug company, spun off from Abbott Laboratories in 2013, that you might want to consider for your long-term portfolio. One of the biggest green flags for investing in the company is its dividend.

ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.

The company is dealing with declining sales of its former cash-cow drug Humira.

Abbvie Inc (NYSE:ABBV) shares moved higher after the pharma company announced it has secured extended patent protection for its blockbuster autoimmune drug RINVOQ (upadacitinib). It said in a regulatory filing that it has reached settlements with all generic manufacturers that had filed applications to produce generic versions of RINVOQ, effectively extending US patent protection until April 2037, assuming pediatric exclusivity is granted.

AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts.

The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.

Shares of AbbVie (ABBV 3.95%) were jumping 4.2% higher as of 11:37 a.m. ET on Thursday.

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

AbbVie Inc. ABBV stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, marketed by the company as Rinvoq.

AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq, until 2037.